Celldex Therapeutics (CLDX) Stock
Clinical stage biotech developing experimental cancer treatments. Here's the price, business snapshot, and what's worth knowing about Celldex Therapeutics in June 2026.
Celldex Therapeutics (CLDX) is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies, principally for oncology and immune-related diseases. Investors should know the company’s value stems from a pipeline of experimental candidates that must clear multiple clinical and regulatory milestones before potential commercialisation. With a market capitalisation of about $1.85bn, Celldex is a small-cap biotech and typically more volatile than established pharmaceutical firms. Key upside catalysts include positive clinical trial readouts, regulatory approvals and strategic partnerships; key risks include trial failures, regulatory setbacks, competition and the potential need for additional financing. The stock is generally suited to investors who accept high binary risk, long development timelines and no near-term dividend income. This summary is educational only and not personal advice; values can rise and fall and past performance is not a reliable guide to future returns.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying CellDex stock, expecting its price to rise to $53.2 in the future.
Financial Health
Celldex Therapeutics is making some revenue but has limited cash flow and book value.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring CLDX
Could Dermatology Biologics Unlock Predictable Revenue?
Eli Lilly's eczema drug EBGLYSS has demonstrated sustained, multi-year effectiveness, highlighting the lucrative potential of targeted biologic therapies. This clinical milestone validates the broader dermatology market, creating opportunities for biopharmaceutical companies developing innovative skin treatments.
Published: 28 March 2026
Explore BasketPharma Stocks: Could Pipeline Power Drive Growth?
Pharmaceutical giant Roche boosted its earnings outlook, fueled by strong sales of its innovative cancer, immunology, and diagnostic products. This success highlights a broader investment opportunity in leading drugmakers with powerful research and development engines poised for growth.
Published: 23 October 2025
Explore BasketFDA Cancer Warning: Beyond the Treatment Headlines
The FDA's new boxed warning for a major cancer therapy from Johnson & Johnson and Legend Biotech highlights the serious side effects of advanced treatments. This focus creates an investment opportunity in companies that develop drugs and therapies to help manage these adverse reactions, improving patient quality of life.
Published: 12 October 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Catalysts
Clinical readouts and regulatory milestones can materially affect value; positive data may drive upside, though trial outcomes are uncertain.
Binary Clinical Risk
Many biotech outcomes are binary — success or failure in trials — which can lead to sharp share price moves and heightened volatility.
Funding & Partnerships
Partnerships or capital raises can accelerate development or dilute shareholders; monitor announcements that affect cash runway and strategic direction.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
